Symbols

EYPT

EyePoint·NASDAQ

--(--)

EYPT fundamentals

EYPT Q4 2025 Earnings

EyePoint (EYPT) released its earnings on Mar 4, 2026: revenue was 620.00K (YoY -94.66%), beat estimates; EPS was -0.81 (YoY -26.56%), missed estimates.

Revenue / YoY

620.00K

-94.66%

EPS / YoY

-0.81

-26.56%

Report date

Mar 4, 2026

EYPT Earnings Call Summary for Q4,2025

$306M Cash Cushion: Funds operations into Q4 2027, supporting Phase III wet AMD (mid-2026) and DME (H2 2027) readouts.
DURAVYU Clinical Strength: +2.1 letters vs EYLEA in wet AMD, 4-week anatomical improvements in DME, with 5.8% cataract incidence.
Commercial Momentum: New CCO Mike Campbell leads U.S. launch prep; manufacturing facility at scale.
Key Risk: Regulatory uncertainty around single-trial approvals for non-rare diseases.
Differentiation: 6-month dosing (60% fewer injections vs EYLEA), IL-6 inhibition for faster visual acuity gains.

Earnings

EPS

Revenue

Revenue & Expenses

EYPT has released its 2025 Q4 earnings report, with revenue of 620.00K, reflecting a YoY change of -94.65%, and net profit of -67.61M, showing a YoY change of -63.31%. The Sankey diagram below clearly presents EYPT's revenue sources and cost distribution.

Key Indicators

EyePoint (EYPT) key financial stats and ratios, covering profitability, financial health, and leverage.

Income Statement

EyePoint (EYPT)'s revenue and profit trends over recent years, visualized with a waterfall chart to showcase the revenue-to-profit funnel.

Trend

Breakdown

Balance Sheet

EyePoint (EYPT)'s asset and liability trends over recent years, visualized with a waterfall chart to illustrate changes in its asset-liability structure.

Trend

Breakdown

Cash Flow

EyePoint (EYPT)'s cash flow trends over recent years, visualized with a waterfall chart to illustrate changes in its operating, investing, and financing cash flows.

Trend

Breakdown